Abstract Glucagon-like-peptide-1 (GLP1) analogs may induce thyroid or pancreatic diseases
in animals, raising questions about their use in diabetic patients. There is, however …

Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

The incidence of type 2 diabetes in developed countries is increasing yearly with a
significant negative impact on patient quality of life and an enormous burden on the …

Glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Abstract Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that, when given
exogenously, is capable of normalizing blood glucose in individuals with type 2 diabetes …

Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor
agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have recently …